Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850498 · ClinicalTrials.gov registry record
Epilepsy Motion Sensing
A clinical trial of Epilepsy, sponsored by MedtronicNeuro.
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT01850498: Completed study of Epilepsy, sponsored by MedtronicNeuro.
NCT01850498 is a study of Epilepsy that has completed, run by MedtronicNeuro. The registered enrollment target is 19 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01850498, a study of Epilepsy, has completed, sponsored by MedtronicNeuro.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate patient motion during seizures.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-04 |
What the finished NCT01850498 record still lists
NCT01850498 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT01850498 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01850498 about?
NCT01850498 is a clinical study titled "Epilepsy Motion Sensing". Evaluate patient motion during seizures.
What is the current status of trial NCT01850498?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2012-05. Estimated completion is 2013-04.
What conditions does trial NCT01850498 study?
This clinical trial studies the following conditions: Epilepsy.
Who is sponsoring clinical trial NCT01850498?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01850498 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01850498's enrollment target sits among peer trials
19 138th of 160 higher than 23 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia